Search for a trial

Generation of urothelial cancer organoids to investigate tumor biology in organoids and to perform drug sensitivity testing.

Primary objective:To establish and propagate a bladder cancer / immune cell co-culture model to study patient response to immunotherapy ex vivo. (Can organoid and immune cell co-cultures be maintained for 3 passages?) Protocols will be improved…

A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

This study has been transitioned to CTIS with ID 2023-507187-39-00 check the CTIS register for the current data. The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk…

Safely reduce cystoscopic evaluations for microscopic Hematuria patients (SeARCH Trial).

To assess the clinical impact of implementing a molecular urine test in the diagnostic workup of patients presenting with microscopic hematuria.

Expression of prostate specific membrane antigen (PSMA) in soft tissue sarcomas and urothelial cell carcinomas: implications for tumour-specific molecular imaging and treatment?

This pilot study aims to investigate the PSMA expression in the biopsy material of advanced soft tissue sarcomas and advanced urothelial cell carcinomas, and in case of high PSMA expression, to investigate whether this correlates with high tracer…

A randomized, placebo-controlled three-way cross-over study to compare the pulsatile intravaginal delivery of oxybutynin versus oral administration.

Primary• To compare the anticholinergic side effects between repeated intravaginal administration of oxybutynin with the vaginal MedRing device and repeated oral administrationSecondary• To explore the pharmacokinetics of oxybutynin and its main…

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A

This study has been transitioned to CTIS with ID 2023-506384-34-00 check the CTIS register for the current data. Primary:- To assess the safety and tolerability of MK2140- To evaluate objective response rate (ORR) of MK2140 as assessed by BICR per…